Lion Point Capital
Latest statistics and disclosures from Lion Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SMTC, IWM, MRNS, ARDX, MIST, and represent 88.79% of Lion Point Capital's stock portfolio.
- Added to shares of these 6 stocks: SMTC, MIST, HARP, NFYS, AMLX, REPL.
- Started 2 new stock positions in NFYS, AMLX.
- Reduced shares in these 8 stocks: , BATL, DRRX, MCRB, MIRM, ARDX, MRNS, CVX.
- Sold out of its positions in CVX, DRRX, SPY.
- Lion Point Capital was a net seller of stock by $-18M.
- Lion Point Capital has $200M in assets under management (AUM), dropping by -10.94%.
- Central Index Key (CIK): 0001643354
Tip: Access up to 7 years of quarterly data
Positions held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Lion Point Capital
Lion Point Capital holds 29 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Semtech Corporation (SMTC) | 55.7 | $111M | +2% | 5.1M | 21.91 |
|
Ishares Tr Russell 2000 Etf Put Option (IWM) | 16.6 | $33M | 165k | 200.71 |
|
|
Marinus Pharmaceuticals Com New (MRNS) | 11.6 | $23M | 2.1M | 10.87 |
|
|
Ardelyx (ARDX) | 3.6 | $7.1M | -2% | 1.2M | 6.20 |
|
Milestone Pharmaceuticals (MIST) | 1.4 | $2.8M | +266% | 1.7M | 1.67 |
|
Harpoon Therapeutics Com New (HARP) | 1.3 | $2.6M | +177% | 229k | 11.37 |
|
Burgerfi International (BFI) | 1.2 | $2.4M | 2.7M | 0.86 |
|
|
Kiniksa Pharmaceuticals Com Cl A (KNSA) | 1.1 | $2.3M | 131k | 17.54 |
|
|
Insmed Com Par $.01 (INSM) | 1.1 | $2.2M | 70k | 30.99 |
|
|
Battalion Oil Corp (BATL) | 1.1 | $2.1M | -41% | 222k | 9.61 |
|
Cymabay Therapeutics (CBAY) | 1.0 | $1.9M | 82k | 23.62 |
|
|
Fennec Pharmaceuticals (FENC) | 0.6 | $1.2M | 110k | 11.22 |
|
|
Avadel Pharmaceuticals Sponsored Adr (AVDL) | 0.6 | $1.1M | 80k | 14.12 |
|
|
Enphys Acquisition Corp Cl A Ord Shs (NFYS) | 0.4 | $834k | NEW | 78k | 10.67 |
|
Syndax Pharmaceuticals (SNDX) | 0.4 | $746k | 35k | 21.61 |
|
|
Bluebird Bio (BLUE) | 0.4 | $733k | 531k | 1.38 |
|
|
Travere Therapeutics (TVTX) | 0.4 | $701k | 78k | 8.99 |
|
|
Travere Therapeutics Note 2.250% 3/0 (Principal) | 0.3 | $671k | 1.0M | 0.67 |
|
|
Humacyte (HUMA) | 0.3 | $667k | 235k | 2.84 |
|
|
Seres Therapeutics (MCRB) | 0.2 | $477k | -50% | 341k | 1.40 |
|
Mirum Pharmaceuticals (MIRM) | 0.2 | $399k | -50% | 14k | 29.52 |
|
Replimune Group (REPL) | 0.2 | $358k | +21% | 43k | 8.43 |
|
Lumos Pharma (LUMO) | 0.1 | $289k | 91k | 3.18 |
|
|
Amylyx Pharmaceuticals (AMLX) | 0.1 | $206k | NEW | 14k | 14.72 |
|
Aadi Bioscience (AADI) | 0.1 | $167k | 82k | 2.02 |
|
|
Aclaris Therapeutics (ACRS) | 0.1 | $122k | 116k | 1.05 |
|
|
Burgerfi International *w Exp 12/16/202 (BFIIW) | 0.0 | $94k | 2.1M | 0.04 |
|
|
Microsoft Corporation (MSFT) | 0.0 | $38k | 100.00 | 376.04 |
|
|
Alphabet Cap Stk Cl C (GOOG) | 0.0 | $14k | 100.00 | 140.93 |
|
Past Filings by Lion Point Capital
SEC 13F filings are viewable for Lion Point Capital going back to 2015
- Lion Point Capital 2023 Q4 filed Feb. 14, 2024
- Lion Point Capital 2023 Q3 filed Nov. 14, 2023
- Lion Point Capital 2023 Q2 filed Aug. 14, 2023
- Lion Point Capital 2023 Q1 filed May 15, 2023
- Lion Point Capital 2022 Q4 filed Feb. 14, 2023
- Lion Point Capital 2022 Q3 filed Nov. 14, 2022
- Lion Point Capital 2022 Q2 filed Aug. 15, 2022
- Lion Point Capital 2022 Q1 filed May 16, 2022
- Lion Point Capital 2021 Q4 filed Feb. 14, 2022
- Lion Point Capital 2021 Q3 filed Nov. 15, 2021
- Lion Point Capital 2021 Q2 filed Aug. 16, 2021
- Lion Point Capital 2021 Q1 restated filed May 19, 2021
- Lion Point Capital 2021 Q1 filed May 17, 2021
- Lion Point Capital 2020 Q4 filed Feb. 16, 2021
- Lion Point Capital 2020 Q3 filed Nov. 16, 2020
- Lion Point Capital 2020 Q2 filed Aug. 14, 2020